Matrix metalloproteinases and uveal melanoma
Pathophysiological Aspects of Proteases in Cancer, Page: 75-89
2025
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Book Chapter Description
Uveal melanoma (UM) is the malignant intraocular tumor characterized by the uncontrolled proliferation of melanocytes primarily in the choroid. Liver is the main anatomic location of the secondary tumor when metastasized. There is no standard therapy to manage the disease. Matrix metalloproteinases (MMPs) have been extensively investigated due to their multifaceted role in numerous pathological conditions including cancer. MMP-2 has been proposed as a prognostic biomarker in UM pathology almost 25 years ago. Since then, other MMPs including MMP-1 and MMP-9 are gradually gaining significant attention in this regard. This chapter provides an up-to-date summary of the most advanced knowledge of molecular and genetic basis of UM, impact of altered MMP/tissue inhibitor of metalloproteinase (TIMP) interaction, and dysregulated extracellular matrix (ECM) homeostasis in UM metastasis with a focus of potential use of a few MMP family members as prognostic biomarkers.
Bibliographic Details
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know